On April 12, QureBio that invested and incubated by Viva BioInnovator, announced that its self-developed bispecific antibody Q-1802 received a notification of drug clinical trial approval from National Medical Products Administration on April 2, 2022 for Phase I/II clinical trial of preliminary efficacy and safety tolerability in combination with standard therapy in patients with gastrointestinal tumors.
Previously, the project has successfully completed the IND application in China and the United States. It has successfully advanced the Phase I clinical study of Q-1802 safety and efficacy exploration. Results of the Phase I partial safety study will be presented at the June 2022 ASCO Annual Meeting.
